Clinical trials: Psoriasis Patients
Healthy Volunteers, Mild to Moderate Psoriasis
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
The first-in-human study will be performed in healthy volunteers and patients with a chronic inflammatory skin disease. The primary objective is to evaluate the safety, tolerability and pharmacokinetics of increasing doses of…
- Trial name
- NCT05965089
- Testing
- AX-202
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Arxx Therapeutics
Psoriasis (PsO), Vitiligo Vulgaris
Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
Primary objective: The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis…
- Conditions
- Psoriasis (PsO), Vitiligo Vulgaris, Atopic Dermatitis, Areata Alopecia
- Trial name
- STIGMADERM (NCT06801821)
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Ankylosing Spondylitis (AS), Psoriasis
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.
- Conditions
- Ankylosing Spondylitis (AS), Psoriasis, Rheumatoid Arthritis (RA)
- Trial name
- ADMIT (NCT03339089)
- Where
- 10 sites in China
- Volunteers
- 224 people
- Sponsor
- AbbVie
Plaque Psoriasis Patients
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy, safety, PK characteristics of ICP-488 in Chinese adults with moderate to severe plaque psoriasis.
- Trial name
- NCT06842199
- Testing
- ICP-488 Tablets
- Where
- 46 sites in China
- Volunteers
- 383 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Psoriasis, Psoriatic-arthritis
PsoBest - The German Psoriasis Registry
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.
- Trial name
- NCT01848028
- Where
- Germany
- Volunteers
- 3,500 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Plaque Psoriasis
DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD01 spray to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to Comp01 lotion when applied twice daily for 15 days.
- Trial name
- BDS1307 (NCT02070965)
- Testing
- DFD01 Spray, Comp01 Lotion
- Where
- 12 sites in United States
- Volunteers
- 75 people
- Sponsor
- Primus Pharmaceuticals
Chronic Plaque Psoriasis
Chronic Plaque Psoriasis (Ps) Registry
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
- Trial name
- NCT00799877
- Where
- 339 sites in United States, Austria and 12 more
- Volunteers
- 6,065 people
- Sponsor
- AbbVie
Generalized Pustular Psoriasis
HB0034 in Patients With Generalized Pustular Psoriasis (GPP)
This is a study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of HB0034 in adult patients with generalized pustular psoriasis (GPP ).
- Trial name
- NCT05512598
- Testing
- HB0034
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab
The purpose of this study is to assess whether or not adalimumab (Humira®) can influence pain medication in participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) with or without…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01273519
- Where
- 15 sites in Austria
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
Scalp Psoriasis
Efficacy and Safety of Xamiol® Gel Compared to Calcipotriol Scalp Solution in Patients With Scalp Psoriasis
The purpose of this study is to compare the clinical efficacy of once daily treatment for 4 weeks with Xamiol® gel (calcipotriol plus betamethasone) with twice daily treatment for 4 weeks with Calcipotriol Scalp Solution in…
- Trial name
- NCT01195831
- Testing
- Xamiol® gel, Calcipotriol scalp solution
- Where
- 9 sites in China
- Volunteers
- 244 people
- Sponsor
- LEO Pharma
Psoriasis
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- X-PLORE (NCT01483599)
- Testing
- CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg)
- Where
- 40 sites in United States, Belgium and 3 more
- Volunteers
- 293 people
- Sponsor
- Janssen Inc.
Plaque Psoriasis
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3)
- Trial name
- INDUS-3 (NCT04855721)
- Testing
- AUR101
- Where
- 25 sites in United States
- Volunteers
- 141 people
- Sponsor
- Aurigene Discovery Technologies Limited
Generalized Pustular Psoriasis
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine medical practice.
- Trial name
- NCT06886009
- Testing
- Spevigo®
- Where
- 4 sites in South Korea
- Sponsor
- Boehringer Ingelheim
Plaque Psoriasis
Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients
Psoriasis vulgaris is associated with significant comorbidity including depression, increased risk of cardiovascular events, diminished quality of life, as well as overall increased mortality.
- Trial name
- NCT06370156
- Testing
- Adalimumab
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Psoriasis
Primary UVB-311nm and Adalimumab in Psoriasis Patients
Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis.
- Trial name
- NCT00638261
- Testing
- UVB-311nm
- Where
- Austria
- Volunteers
- 4 people
- Sponsor
- Medical University of Graz
Palmoplantar Pustulosis
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab.
- Trial name
- NCT04493424
- Testing
- Spesolimab
- Where
- 66 sites in United States, Australia and 12 more
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT01208090
- Testing
- ACT-128800
- Where
- 67 sites in Austria, Belgium and 15 more
- Volunteers
- 326 people
- Sponsor
- Actelion
SARS-CoV-2, Systemic Lupus Erythematosus
Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients…
- Conditions
- SARS-CoV-2, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren's Syndrome
- Trial name
- COVCALL (NCT04345159)
- Testing
- Questionnaire by phone call
- Where
- France
- Volunteers
- 572 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Plaque Type Psorisis
A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)
A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis
- Trial name
- SUPREME (NCT02394561)
- Testing
- Secukinumab
- Where
- 45 sites in Italy
- Volunteers
- 434 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept
This study will provide data on additional therapeutic benefits in administering Adalimumab in patients with plaque psoriasis that showed an unsatisfactory response after at least 3 months of treatment with etanercept.
- Trial name
- NCT00927069
- Testing
- Adalimumab every other week, Adalimumab Every Week
- Where
- 12 sites in Canada
- Volunteers
- 85 people
- Sponsor
- Innovaderm Research Inc.